César has a Ph.D. in Green Chemistry and Catalysis from the University of St Andrews and R&D experience in multiple research universities around the globe. He co-leads business development.
By Dr. Ashish Punia, Ph.D. Merck & Co., Rahway, NJ A considerable portion of small molecule pharmaceutical drugs suffer from poor aqueous solubility. Amorphous solid dispersion (ASD) is a...
Ashish Punia is a Principal Scientist in the Materials and Biophysical Characterization Group at Merck & Co., Inc., Rahway NJ. Prior to joining Merck, he received his PhD in...
By Prof. Changquan Calvin Sun, Ph.D. Professor, University of Minnesota The development of a quality tablet product requires overcoming deficiencies in pharmaceutical properties of tablets to meet several performance...
By Prof. Ronald Siegel, Professor and Department Head, Department of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455 For many low solubility drugs, the crystalline form is unfavorable due to...
Professor Siegel received his ScD degree in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology (MIT) in 1984. From 1984 to 1998 he was on the...
By Samuel kyeremateng, Ph.D. AbbVie, North Chicago, IL Small molecule solid dosage drug product with the drug in the crystalline state is typically preferred due its more desirable properties...
Samuel Kyeremateng, Ph.D. is a Principal Research Scientist and Head of the Material Science and Formulation Modeling Group in NCE Formulation Sciences at AbbVie Deutschland GmbH & Co. KG....
Dr. Sun is Professor of Pharmaceutics in the Department of Pharmaceutics, University of Minnesota, USA. Dr. Sun’s research focuses on formulation development of tablet products through appropriate application of...
